Product Data Sheet

β-Aminoarteether maleate

Cat. No.: HY-137553A

CAS No.: 133162-25-1

Molecular Formula: C₂₁H₃₃NO₉

Molecular Weight: 443.49

Target: NOD-like Receptor (NLR)

Pathway: Immunology/Inflammation

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

BIOLOGICAL ACTIVITY

Description	$\beta\text{-}Aminoartee ther \ maleate \ (SM934) \ is \ an \ Artemisinin \ derivative \ with \ or ally \ active. \ \beta\text{-}Aminoartee ther \ maleate \ can \ be \ used \ for \ an \ be \ or \ an \ or \ o$
	inflammation and autoimmune disease research, such as lupus diseases ^[1] .

In Vitro β -Aminoarteether (SM934;10 μ M; 24 hours) treatment directly enhances IL-10 production and suppresses IL-12/23p40 production in primary peritoneal macrophages with IFN- γ stimulation^[1].

In vitro, β -Aminoarteether (SM934) could suppress the Th1 and Th17 polarization, but exerted no influence on Treg differentiation^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

 $\text{In Vivo} \hspace{1cm} \beta\text{-Aminoarteether (SM934; 1-10 mg/kg; oral administration; daliy; for 3 months) treatment significantly delays the } \\$

progression of glomerulonephritis and increases the survival rate of NZB/W F1 mice. β -Aminoarteether treatment promots the IL-10 production of macrophages from NZB/W F1 mice^[1].

 $\label{eq:mce} \mbox{MCE has not independently confirmed the accuracy of these methods. They are for reference only.}$

Animal Model:	Female NZB/W F1 mice (Six and half months old) $^{[1]}$
Dosage:	1 mg/kg, 3 mg/kg, and 10 mg/kg
Administration:	Oral administration; daliy; for 3 months
Result:	Significantly delayed the progression of glomerulonephritis and increased the survival rate of NZB/W F1 mice.

REFERENCES

[1]. Yang FM, Fan D, Yang XQ, et al. The artemisinin analog SM934 alleviates dry eye disease in rodent models by regulating TLR4/NF-κB/NLRP3 signaling. Acta Pharmacol Sin. 2021;42(4):593-603.

[2]. Li-Fei Hou, et al. SM934 treated lupus-prone NZB × NZW F1 mice by enhancing macrophage interleukin-10 production and suppressing pathogenic T cell development. PLoS One. 2012;7(2):e32424.

 $\label{lem:caution:Product} \textbf{Caution: Product has not been fully validated for medical applications. For research use only.}$

Tel: 609-228-6898 Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com